ABBV vs MAR: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Marriott International, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-20.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Marriott International, Inc. · Consumer Cyclical
$366.24
-3.4% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MAR |
| Current Price |
$261.07 |
$366.24 |
| Fair Value Estimate |
$264.30 |
$353.64 |
| Upside to Fair Value |
+1.2%
|
-3.4%
|
| Market Cap |
$461.3B |
$96.6B |
| Forward P/E |
128.0x
|
—
|
| EV / EBITDA |
31.0x
|
23.8x
|
| Price / Sales |
7.3x
|
3.7x
|
| Price / FCF |
22.1x
|
31.6x
|
| Revenue Growth YoY |
+12.4%
|
+6.2%
|
| Gross Margin |
70.7%
|
21.4%
|
| Operating Margin |
27.6%
|
16.0%
|
| Return on Equity |
68.0%
|
-74.1%
|
| Dividend Yield |
0% |
0.75% |
| FCF Yield |
4.52%
|
3.17%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Marriott International is a global asset-light hotel franchisor, manager and licensor whose high-quality brands, nearly 283 million Bonvoy members, more than 9,900 properties across 146 countries and record 4,107-property development pipeline create meaningful network, distribution and brand advantages. Q1 2026 demonstrated resilient underlying fee economics: adjusted revenue excluding cost-reimb…
Accumulation Zones
| Metric |
ABBV |
MAR |
| Zone Low |
$198.23 |
$265.23 |
| Zone High |
$224.66 |
$300.59 |
| In Buy Zone? |
No
|
No
|